Andreas Marquardt

Andreas has over 20 years of international research experience, from biotech start-ups to the pharmaceutical industry.

Having studied biology to PhD level in Germany with a thesis in human genetics, he started his professional career in 2000 with Ingenium Pharmaceuticals, Munich, where he used his knowledge and skills in genomics, especially in positional cloning of disease genes, to contribute to the company’s target discovery programs. During his seven years with Ingenium, he took on various roles, from Scientist to Director ADME, with growing responsibilities, eventually being in charge of pre-clinical studies in support of small molecule drug development. In 2008, Andreas accepted an offer from Takeda Singapore and moved to Asia.

Over the next six years he worked for the company as a Principal Scientist in Singapore and Japan, gaining expertise in the design and construction of transgenic platforms, including large-scale humanization of the murine immunoglobulin loci. In 2014, Andreas joined Kymab in Cambridge, UK, where he became instrumental in the engineering of the company’s next-generation antibody discovery platform.

In January 2019, he joined PetMedix as the Head of Genome Engineering, overseeing the development of both Ky9TM and FelyneTM transgenic antibody discovery platforms.